Onconova Therapeutics Inc
NASDAQ:TRAW

Watchlist Manager
Onconova Therapeutics Inc Logo
Onconova Therapeutics Inc
NASDAQ:TRAW
Watchlist
Price: 2.24 USD -3.86%
Market Cap: 17.9m USD

Wall Street
Price Targets

TRAW Price Targets Summary
Onconova Therapeutics Inc

Wall Street analysts forecast TRAW stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TRAW is 8.16 USD with a low forecast of 8.08 USD and a high forecast of 8.4 USD.

Lowest
Price Target
8.08 USD
261% Upside
Average
Price Target
8.16 USD
264% Upside
Highest
Price Target
8.4 USD
275% Upside
Onconova Therapeutics Inc Competitors:
Price Targets
600750
Jiang Zhong Pharmaceutical Co Ltd
18% Upside
ETON
Eton Pharmaceuticals Inc
92% Upside
ALDVI
Advicenne SA
127% Upside
1477
Ocumension Therapeutics
34% Upside
MARI
Marinomed Biotech AG
171% Upside
ORX
Orexo AB
35% Upside
HYPE3
Hypera SA
31% Upside

Revenue
Forecast

Revenue Estimate
Onconova Therapeutics Inc

For the last 2 years the compound annual growth rate for Onconova Therapeutics Inc's revenue is 0%. The projected CAGR for the next 2 years is 16%.

0%
Past Growth
16%
Estimated Growth
Estimates Accuracy
3%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Onconova Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Net Income
Forecast

Net Income Estimate
Onconova Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-90%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is TRAW's stock price target?
Price Target
8.16 USD

According to Wall Street analysts, the average 1-year price target for TRAW is 8.16 USD with a low forecast of 8.08 USD and a high forecast of 8.4 USD.

What is Onconova Therapeutics Inc's Revenue forecast?
Projected CAGR
16%

For the last 2 years the compound annual growth rate for Onconova Therapeutics Inc's revenue is 0%. The projected CAGR for the next 2 years is 16%.

Back to Top